PharmaShots | Incisive News in 3 Shots

Subscribe Now

immunic

Immunic Reports P-IIb Study (CALDOSE-1) Results of IMU-838 (vidofludimus calcium) for Moderate-to-Severe Ulcerative Colitis

Immunic Reports P-IIb Study (CALDOSE-1) Results of IMU-838 (vidofludimus calcium) for Moderate-to-Severe Ulcerative Colitis

April 5, 2023

Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple Sclerosis

Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple...

November 18, 2022

Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Colitis at ECCO 2022

Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Co...

February 21, 2022

PharmaShots Weekly Snapshots (October 25 - 29, 2021)

PharmaShots Weekly Snapshots (October 25 - 29, 2021)

October 29, 2021

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

September 24, 2021

PharmaShots Weekly Snapshots (July 05 - 09, 2021)

PharmaShots Weekly Snapshots (July 05 - 09, 2021)

July 9, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us